The role of matrix metalloproteinase expression levels in the pathogenesis of tympanosclerosis
European Archives of Oto-Rhino-Laryngology · 2025
DOI: 10.1007/s00405-025-09509-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2025. Verfasst von Semih Van und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology and Head & Neck Surgery Adıyaman Training and Research Hospital, Adıyaman, Turkey. semih.van1@gmail.com. Hauptthemen laut MEDLINE: Myringosclerosis, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Otitis Media. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Samsun University.
Abstract (Originalsprache)
Purpose
Tympanosclerosis is a disease characterized by the accumulation of hyaline calcareous deposits in the tympanic membrane, tympanic cavity, ossicular chain, ligaments, and rarely, in the mastoid. Matrix metalloproteinases, which are involved in physiological and pathologic processes, are also likely to play a role in tympanosclerosis. In our study, we aimed to investigate the presence of MMP 2 and 9 in patients with chronic otitis media with tympanosclerosis and its possible effect on tympanosclerosis severity and prognosis.
Methods
In our study, 45 patients with myringosclerosis or myringosclerosis and intratympanic sclerosis who underwent endoscopic transcanal tympanoplasty due to COM (chronic otitis media) were included in the study group, and 35 patients with only COM, without tympanosclerosis, were included in the control group. Immunohistochemical staining of the mucosa samples of the eardrum and middle ear were compared with MMP-2 and MMP-9 in the study and control groups.
Results
The rate of MMP-2 staining (64.3%) was higher than the control group (42.9%), and the rate of MMP-9 staining (16.7%) was lower than the control group (51.4%) ( p < 0.05). The rate of MMP-9 staining in the middle ear mucosa samples (31.0%) was statistically lower than the control group (57.1%) ( p < 0.05).
Conclusion
In our study, high levels of MMP-2 staining in the study group and low levels of MMP-9 staining in the control group help to elucidate the complex relationship between both metalloproteinases. Compared with the inadequacy of animal models of tympanosclerosis to mimic the chronic process, our study reveals the late results of MMP-2 and MMP-9 in patients with tympanosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology and Head & Neck Surgery Adıyaman Training and Research Hospital, Adıyaman, Turkey. semih.van1@gmail.com.
- Department of Otolaryngology and Head & Neck Surgery, Samsun University Samsun Training and Research Hospital, Samsun, Turkey.
- Department of Medical Pathology, Samsun University Samsun Training and Research Hospital, Samsun, Turkey.
- Department of Public Health, Samsun University Samsun Training and Research Hospital, Samsun, Turkey.
- Department of Otolaryngology and Head and Neck Surgery, Samsun Training and Research Hospital, Samsun, Turkey.
Förderung
- Samsun University
Zitieren
APA
Van, S., Özdemir, D., Şahin, S. K., Öztürk, Ş., Mehel, D. M., & Çeçen, A. (2025). The role of matrix metalloproteinase expression levels in the pathogenesis of tympanosclerosis. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-025-09509-3
Vancouver
Van S, Özdemir D, Şahin SK, Öztürk Ş, Mehel DM, Çeçen A. The role of matrix metalloproteinase expression levels in the pathogenesis of tympanosclerosis. European Archives of Oto-Rhino-Laryngology. 2025. doi:10.1007/s00405-025-09509-3
BibTeX
@article{Van2025,
author = {Van, Semih and Özdemir, Doğukan and Şahin, Seda Koç and Öztürk, Şule and Mehel, Dursun Mehmet and Çeçen, Ayşe},
title = {The role of matrix metalloproteinase expression levels in the pathogenesis of tympanosclerosis},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2025},
doi = {10.1007/s00405-025-09509-3}
}
EUVIMED